Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/76334
Title: The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
Authors: Dranitsaris, G
Molassiotis, A 
Clemons, M
Roeland, E
Schwartzberg, L
Dielenseger, P
Jordan, K
Young, A
Aapro, M
Keywords: Emesis
Nausea
Risk
Prediction
Cancer
CINV
Issue Date: 2017
Publisher: Oxford University Press
Source: Annals of oncology, 2017, v. 28, no. 6, p. 1260-1267 How to cite?
Journal: Annals of oncology 
Abstract: Background: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of >= grade 2 CINV (>= 2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. Patients and methods: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at <0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0-32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. Results: Over 4197 chemotherapy cycles, 42.2% of patients experienced >= grade 2 CINV. Eight risk factors were identified: patient age <60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an area-under-the-curve of 0.69 (95% CI: 0.67-0.70). Before to each cycle of therapy, patients with risk scores >= 16 units would be considered at high risk for developing >= grade 2 CINV. Conclusions: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner.
URI: http://hdl.handle.net/10397/76334
ISSN: 0923-7534
EISSN: 1569-8041
DOI: 10.1093/annonc/mdx100
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

9
Citations as of May 26, 2018

WEB OF SCIENCETM
Citations

5
Citations as of May 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.